Project description
Tumour bioprinting: the future of drug discovery
Current approaches for studying tumour biology and for performing drug screening rely on 2D cell cultures and animal models. However, they do not accurately reflect the size, heterogeneity and vascularity of the human tumour microenvironment. Scientists of the EU-funded TUMOURPRINT project are working on a disruptive bioprinting technology capable of fabricating tissue models with high fidelity. The technology uses live cells in combination with specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development. Results are expected to revolutionise the drug development processes by offering cancer models in an automated, precise and reproducible way.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineoncology
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringrobotics
Programme(s)
Funding Scheme
SME-2 - SME instrument phase 2
Coordinator
BICO GROUP AB
Net EU contribution
€ 2 450 327,25
Address
Arvid Wallgrens Backe 20
413 46 Goteborg
Sweden
413 46 Goteborg
Sweden
See on map
Region
Södra Sverige Västsverige Västra Götalands län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 050 140,25